<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639857</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-17-13680</org_study_id>
    <nct_id>NCT03639857</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone</brief_title>
  <official_title>A Comparative Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Weinstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Central Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the efficacy of 532nm Potassium Titanyl Phosphate (KTP) laser and
      1064 nm Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) laser as adjuncts to topical
      corticosteroids in the treatment of cutaneous lupus erythematosus versus topical
      corticosteroids alone.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Time and resource constraints
  </why_stopped>
  <start_date type="Actual">August 17, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Limited CLASI</measure>
    <time_frame>3 months</time_frame>
    <description>The investigators are using a limited CLASI scoring system to classify specific lesions the investigators are measuring. The total limited CLASI reflects the sum of both active and damage CLASI, resulting in a score ranging from 0 to 8.
The limited active CLASI for a lesion will include the following:
Erythema (ranging from 0 = absent to 3 = dark red/purple)
Scale/Hypertrophy (ranging from 0 = absent to 2 = verrucous/ hypertrophic)
The addition of these scores result in a total limited active CLASI score of the studied lesion, ranging from 0 to 5.
The limited damage CLASI for a lesion will include the following:
Dyspigmentation (0 = absent or 1 = present)
Scarring/Atrophy/Panniculitis (ranging from 0 = absent to 2 = severely atrophic scarring or panniculitis).
The addition of these scores result in a maximum damage score of 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS for Appearance</measure>
    <time_frame>3 months</time_frame>
    <description>The investigators are using a VAS (visual analog scale) to assess both patient and physician assessment of the appearance of the lesion. The scale ranges from 1-10, with 10 being very satisfied and 1 being no satisfaction at all.
A score of 0 will represent a cosmetically fully unsatisfactory result and 10 will represent cosmetically excellent result.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS for Pain</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators are using a VAS (visual analog scale) to assess pain of the lesion. The scale ranges from 1(no pain) to 10(worse pain).
A score of 0 will represent absence of pain and 10 will represent maximal pain.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Cutaneous Lupus</condition>
  <arm_group>
    <arm_group_label>532nm laser and topical corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1064nm laser and topical corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical corticosteroid alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical corticosteroid is applied to the patient's lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>532nm laser</intervention_name>
    <description>532nm laser will be used to treat the lesion in this study arm.</description>
    <arm_group_label>532nm laser and topical corticosteroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1064nm laser</intervention_name>
    <description>1064nm laser will be used to treat the lesion in this study arm.</description>
    <arm_group_label>1064nm laser and topical corticosteroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical corticosteroid</intervention_name>
    <description>The topical corticosteroid will be used to treat the lesion in this study arm.</description>
    <arm_group_label>1064nm laser and topical corticosteroid</arm_group_label>
    <arm_group_label>532nm laser and topical corticosteroid</arm_group_label>
    <arm_group_label>Topical corticosteroid alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adult 18 years of age or older

          -  Ability to rate level of pain

          -  Ability to rate visual satisfaction

          -  At least 2 active lesions of CLE

        Exclusion Criteria:

          -  New or change in systemic medication for cutaneous lupus in past 6 months

          -  Allergy to triamcinolone or betamethasone dipropionate cream

          -  Pregnancy

          -  Currently a prisoner

          -  Unable to read and speak English since consent will only be available in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCF Health Lake Nona Office</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Central Florida</investigator_affiliation>
    <investigator_full_name>David Weinstein</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

